A study of Sapu003 for advanced tumors sensitive to mTOR
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, Sapu003, in people with certain advanced cancers that may respond to mTOR-targeted therapy. It is looking at two groups: postmenopausal women with a type of breast cancer (HR+/HER2-), and adults with kidney, liver, neuroendocrine, or TSC-related tumors. The goal is to see if Sapu003 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of the specific advanced cancers listed: a certain type of breast cancer (HR+/HER2-), kidney cancer, liver cancer, neuroendocrine tumors, or TSC-related tumors.
- You must have tried at least one prior standard treatment that did not work or caused side effects, unless no standard treatment exists.
- You must be taking a stable dose of metformin or a statin medication.
- You must be able to perform daily activities with some help (ECOG score of 0, 1, or 2).
- You cannot be pregnant or breastfeeding, and must use effective birth control during and for a period after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug (sacituzumab tirumotecan) for people with rare types of kidney or bladder cancer that have spread. The drug targets a protein called TROP-2 on cancer cells. The goal is to see if it can shrink tumors or slow the cancer when other treatments have stopped working or are not available.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.